EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Erlotinib Treatment in Colorectal Cancer Suppresses Autophagy Based on KRAS Mutation

Alexander Siegman, Aaron Shaykevich iD, Danbee Chae, Isaac Silverman iD, Sanjay Goel iD, Radhashree Maitra iD

Current Issues in Molecular Biology · 16.07.2024 · 46 (7) · 7530-7547

DOI: 10.3390/cimb46070447 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Current Issues in Molecular Biology, online erschienen am 16.07.2024. Verfasst von Alexander Siegman und 5 weiteren Autor:innen. Beteiligte Einrichtung: Department of Biology, Yeshiva University, New York, NY 10033, USA. Die Arbeit wurde bisher 5-mal zitiert (Crossref) und nennt 44 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: NCI NIH HHS, NIH HHS, Shevet Glaubach Center for Career Strategy and Professional Development of Yeshiva University.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

The KRAS gene is mutated in approximately 45% of colorectal cancer patients. There are currently very few targeted treatments or therapies equipped to directly inhibit KRAS due to its unusual structural intricacies. Erlotinib, an EGFR inhibitor, has previously been demonstrated to reduce cell viability by inducing autophagy in lung cancer cell lines with varying EGFR mutations. In contrast to lung cancer cells, evidence is provided herein for the first time that erlotinib treatment in colorectal cancer (CRC) cell lines reduces autophagy and still results in decreased cell viability. However, the effects of erlotinib in CRC cell lines containing a wildtype KRAS gene were different than in cells carrying a mutant KRAS gene. We show that there is significantly more downregulation of autophagy in KRAS mutant CRC cells compared to KRAS wildtype cells, both at transcriptional and translational levels, suggesting that the KRAS mutation is advantageous for cancer growth, even in the presence of erlotinib. Cell viability results determined that KRAS wildtype CRC cells had significantly more cell death compared to KRAS mutant cells. Using patient mRNA datasets, we showed that there was a significant correlation between the presence of the KRAS mutation and the expression of autophagy proteins. Additionally, through molecular dynamics simulations, we develop a blueprint for KRAS and autophagy protein interaction and the impact of the KRAS mutation on autophagy protein regulation. Overall, this is the first report of erlotinib treatment in CRC cells that assesses autophagy, and we demonstrate that autophagy activity is downregulated in these cells. This effect is not only greater in cells carrying a KRAS mutation compared to wildtype cells, but the KRAS mutant cells also have increased cell viability compared to wildtype cells. We hypothesize that the difference in cell viability and autophagy expression between KRAS mutant and KRAS wildtype cells after treatment with erlotinib can be of therapeutic value to treat CRC patients carrying KRAS mutations.

Schlagwörter

Stichwörter der Autor:innen

EGFRKRASautophagycancercolorectalerlotinib

Autor:innen und Institutionen

  • Department of Biology, Yeshiva University, New York, NY 10033, USA.
  • Department of Medical Oncology, Rutgers Cancer Institute of New Jersey, New Brunswick, NJ 08901, USA.

ORCID-Profile: Aaron Shaykevich, Isaac Silverman, Sanjay Goel, Radhashree Maitra

Förderung

  • NCI NIH HHS
  • NIH HHS
  • Shevet Glaubach Center for Career Strategy and Professional Development of Yeshiva University

Zitieren

APA

Siegman, A., Shaykevich, A., Chae, D., Silverman, I., Goel, S., & Maitra, R. (2024). Erlotinib Treatment in Colorectal Cancer Suppresses Autophagy Based on KRAS Mutation. Current Issues in Molecular Biology, 46(7), 7530-7547. https://doi.org/10.3390/cimb46070447

Vancouver

Siegman A, Shaykevich A, Chae D, Silverman I, Goel S, Maitra R. Erlotinib Treatment in Colorectal Cancer Suppresses Autophagy Based on KRAS Mutation. Current Issues in Molecular Biology. 2024;46(7):7530-7547. doi:10.3390/cimb46070447

BibTeX
@article{Siegman2024,
  author = {Siegman, Alexander and Shaykevich, Aaron and Chae, Danbee and Silverman, Isaac and Goel, Sanjay and Maitra, Radhashree},
  title = {Erlotinib Treatment in Colorectal Cancer Suppresses Autophagy Based on KRAS Mutation},
  journal = {Current Issues in Molecular Biology},
  year = {2024},
  volume = {46},
  number = {7},
  pages = {7530--7547},
  doi = {10.3390/cimb46070447}
}
Kostenlos starten →